Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Viewpoints

PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition

In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk’s acquisition of Prothena’s ATTR amyloidosis program includes PRX004 Shots: The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena’s PRX004 and broader ATTR amyloidosis program Novo Nordisk acquires Prothena’s subsidiary and gets WW rights to the […]Read More

Viewpoints

Pharmashots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on the

In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in an ongoing P-Ib study to treat waldenström’s macroglobulinemia Shots: The ongoing P-Ib clinical trial evaluates the safety & efficacy of mavorixafor + ibrutinib in patients […]Read More